FDAsafety guidance66% confidence
Umendra Life Sciences Private Limited - 721752 - 06/02/2026
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ophthalmology) as Lupin; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Ophthalmology · Anti-VEGF
- Sub-indication
- Ophthalmology
Related signal: FDA Accepts BLA for RANLUSPEC by Lupin Limited